|Dr. Sanjay S. Shukla||Pres, CEO & Director||702.05k||N/A||1972|
|Ms. Jill M. Broadfoot||Chief Financial Officer||516.11k||N/A||1962|
|Ms. Nancy E. Denyes Krueger||Gen. Counsel & Corp. Sec.||477.14k||N/A||1968|
|Xiang-Lei Yang Ph.D.||Founder||N/A||N/A||N/A|
|Ms. Ashlee Dunston||Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Peter Villiger||VP of Corp. Devel.||N/A||N/A||N/A|
|Dr. Ying J. Buechler||Exec. Director of Biologics Devel. & Manufacturing||N/A||N/A||N/A|
|Dr. Melissa A. Ashlock||Sr. Advisor||N/A||N/A||1958|
|Dr. David J. King||Scientific Consultant||N/A||N/A||1959|
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
aTyr Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.